U
DMK

UBS’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

UBS’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-42
Closed -$14K – 10865
2014
Q2 		$14K Buy
42
+21
+100% +$8.25K ﹤0.01% 8537
2014
Q1 		$10K Buy
+21
New +$9.53K ﹤0.01% 8921
2013
Q4 		– Hold
0
– – – 10851

Other funds holding DMK

GP
Grow Partners San Diego, California $4.81M AUM 7.86% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS's DMK Position: Q3 2014 in Review

UBS sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q3 2014, closing a stake of 42 shares — an estimated $14K sold.

UBS first reported a position in DMK in Q1 2014 and held it in 2 quarters. The position peaked at $14K in Q2 2014. 19 funds tracked by Wall St. Rank hold DMK as of Q3 2014.

  • UBS reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q3 2014 after selling out during the quarter.
  • UBS sold 42 DMK Pharmaceuticals Corporation Common Stock shares in Q3 2014, an estimated $14K.
  • UBS first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q1 2014 and held it in 2 quarters.
  • UBS's DMK Pharmaceuticals Corporation Common Stock position peaked at $14K in Q2 2014.
  • 19 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.